JMT601

JMT601 is a first-in-class bispecific fusion protein designed for the treatment of relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma. It combines an anti-CD20 antibody with a signal regulatory protein alpha (SIRPα) fragment that binds to CD47. By simultaneously targeting CD20 and blocking the "don't eat me" signal mediated by CD47, JMT601 enhances both antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), promoting immune-mediated elimination of malignant B cells. The drug is administered intravenously and is currently in Phase 1/2 clinical trials. It has been granted Fast Track Designation by the U.S. FDA for diffuse large B-cell lymphoma[2][3][5][7][8].

Other names

cd20-cd47 bispecific fusion proteincd-20-cd47 bispecific fusion proteincd 20-cd47 bispecific fusion proteinofatumumab-sirpalpha fusion protein